The first phase III clinical mid-term analysis of the new crown vaccine was outstanding

BioNTech/Pfizer today announced the results of an interim analysis of its new coronavirus infection mRNA vaccine BNT162b2 Phase III clinical.
The phase III clinic, which recruited 43,538 volunteers and used two doses of the vaccine and a placebo, was planned to conduct the first interim analysis of 32 infections in two groups, but later expanded to 62 people, with a final analysis requiring 164 infections.
today's analysis is based on data from 94 infected patients seven days after the second vaccine (28 days after the first shot), showing that BNT162b2 is more than 90 percent protected and no serious side effects were found.
Pfizer and BioNTech are preparing to submit emergency listing (EUA) applications for the vaccine.
BNTX and Pfizer rose 13 percent and nearly 8 percent, respectively, and the Dow rose nearly 3 percent.
source analysis Today's results exceeded most experts' expectations, and although detailed data have not been released and the time node may have exaggerated the efficacy, few doubt that the product will have some effect.
even if the efficacy may fluctuate after more data are accumulated, there may not be significant fluctuations.
Because of the severity of the virus, it is estimated that the vaccine has 50-60% protection capacity if the safety is not too big a problem can be marketed, because the efficacy of the vaccine in general plus some common precautions may be effective in controlling the chain of infection.
end of this trial is the number of people who are positive for symptomatic neo-coronavirus, so the prevention of disease-free infections and the risk of reducing severe illness are unknown.
important indicator is conservation persistence, and this experiment cannot be answered.
the effectiveness of the vaccine for different populations has not been announced, and the safety of the entire trial has yet to be observed.
but these problems are unlikely to upset the big picture at this time unless accidental toxicity is later detected.
even if the vaccine is ineffective for some populations and does not reduce the risk of asymptomatic infections and severe illnesses, reducing symptomatic infections by 90 percent has made the core goal of group immunization very easy and safe.
even if it is limited in durability and needs to be played twice a year like influenza, it is not too burdenss.
the vaccine's main task is to restore normalcy to society, not to reduce the risk of a new crown to 0.
from today's announcement is information to see that BNT162b2 has this potential.
of course this product needs to be kept at low temperatures, as high demand for capacity can be a speed limit step.
there are also countries in which large numbers of anti-vaccine groups may refuse to use them and delay the establishment of group immunization.
but this is definitely the most crucial battle against the new crown.
's new coronavirus sequence was announced in January, just 10 months after the development of a safe and effective vaccine shows the power of biotechnology, of course, this time against the new crown vaccine and new drug development speed, intensity, and breadth are unprecedented.
this product is the first time that mRNA technology has produced positive data in Phase III clinically, and it is a miracle that a new technology has become famous in an emergency.
The vaccine is relatively simple and relies heavily on S-protein antibodies because the mRNA vaccine only expresses the protein, but it's surprising to have such an effect, especially given that high-dose antibody drugs are less effective in early-stage infected patients.
success of the mRNA vaccine makes other vaccines more promising, as other types of vaccines also produce S-protein antibodies but may also induce more complex immune responses such as T-cell-mediated immunity.
previously raised concerns about antibody-mediated toxicity and inadequate antibody protection alone have dissipated with the opening of Schrodinger's cat box.
if BNT162b2 does end the new crown epidemic, it will be a legend in pharmaceutical history, just as the U.S. Amateur Ice Team defeated the Soviet pro team at the 1980 Olympics.
A new technology with a blank resume, an ad risk-adient German loner (BNTX has long been Europe's largest private biotech company), a power-powered pharmaceutical giant that has always lacked speed, has accomplished an unstoppable task with maximum efficiency when the world needs it most.
the next time politicians go to court the pharmaceutical industry, it's up to the pharmaceutical industry to end a century of disasters like the new crown.
the final analysis without any unintended toxic side effects, hope that people's lives return to normal.